SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Metabasis Therapeutics , announced today that Dr. Paul Laikind, chairman, CEO and president of Metabasis will present at two investor conferences in November. A business overview and a discussion of the Company’s product pipeline is expected to be provided at both conferences.
Rodman & Renshaw Techvest 7th Annual Healthcare Conference
Dr. Paul Laikind is scheduled to present on November 7, 2005 at 12:40 p.m. Eastern Time during the Rodman & Renshaw Techvest 7th Annual Healthcare Conference at the New York Palace Hotel in New York, NY.
SG Cowen & Co. 6th Annual Global Healthcare Conference
Dr. Paul Laikind is scheduled to present on November 10, 2005 at 10:55 a.m. local time (4:55 a.m. Eastern Time) during the SG Cowen & Co. 6th Annual Global Healthcare Conference at the Hilton Diagonal Mar Hotel in Barcelona, Spain.
To access the live broadcasts and the subsequent archived recordings of both presentations, please log onto the Company’s website at www.mbasis.com under the “Investors” section. The audio recordings and presentations will be archived there for 30 days following the live presentations. Please connect to Metabasis’ website several minutes prior to the start of the presentations to ensure adequate time for any software download that may be necessary.
About Metabasis (www.mbasis.com):
Metabasis Therapeutics is a biopharmaceutical company focused on the discovery, development and eventual commercialization of novel drugs to address some of the world’s most widespread and costly chronic diseases involving pathways in the liver. The Company has established a pipeline that includes clinical stage and preclinical product candidates targeting major diseases with significant unmet medical needs. Targeted diseases include major metabolic diseases such as diabetes, hyperlipidemia and obesity as well as liver diseases such as hepatitis and primary liver cancer. Metabasis has developed several proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic(TM) and HepDirect(TM) technologies. Metabasis is continuing to identify and develop new product candidates using its proprietary technologies and expertise.
Metabasis Therapeutics Inc.
CONTACT: Paul Laikind, Ph.D., Chairman, CEO & President of MetabasisTherapeutics, Inc., +1-858-622-5550
Web site: http://www.mbasis.com/
